How can domestic pharmaceutical companies get rid of the "follower" role?

Pharmaceutical Network Market AnalysisIn the past few years, China's pharmaceutical consumption has grown rapidly, with the pharmaceutical industry's sales revenue growing by an average of 21.4% per yearChina has become one of the world's largest pharmaceutical markets, driven by strong economic growth, increasing urbanization and the demand for medical care brought about by agingDeloitte predicts that China's pharmaceutical market is expected to reach $220 billion by 2020, becoming the world's second-largest pharmaceutical market after the United Stateshow can domestic drug companies get rid of the "follower" role?but it is worth noting that with the continuous development of the pharmaceutical industry, the survival of the fittest in the market has also become the inevitable result of the survival and development of enterprisesIn order to obtain a place in the fierce market competition environment, enterprises need to hone themselves, conform to current events, do the country, the people need products, after all, only good products can win good reputationPharmaceutical companies focus on different areas, accelerate the development of innovative drugs
At present, domestic pharmaceutical companies product research and development hot spots are focusing on innovative drugsThis is due to recent years, China attaches great importance to pharmaceutical innovationEspecially since 2015, the policy environment for innovative drugs has been continuously optimized, the National Innovation-Driven Development Strategy Outline, the 13th Five-Year Plan for National Science and Technology Innovation, the Guide to the Development of the Pharmaceutical Industry and other planning guidelines have set out the goals for the development of innovative drugs, and after special projects have been set up to promote the development of new drugs, the innovation vitality of pharmaceutical companies has been continuously released, and more and more innovative drugs are being marketedit is understood that, as an innovative-driven biopharmaceutical company, Junshi Biohas has been in a leading position in the treatment of cancer immunotherapy, autoimmune diseases and metabolic diseases by virtue of its strong innovative drug discovery capabilities, advanced biotechnology research and development, large-scale production technology of the whole industry chain and the rapid expansion of the research drug portfolio with very market potentialThe Trepri Singer, its heavy-duty PD-1 target, has been approved for sale, and TheRipley Single Resistance and BTLA Mono-Da-Internationalization have set sailIn addition, it has a strong pipeline of 20 innovative pharmaceutical productsin addition to Junshi biological, in recent years, domestic pharmaceutical companies have laid out anti-tumor, endocrine, cardiovascular and other fields of innovative drug research and developmentIn particular, since this year, including Collon Pharmaceuticals, Watson Pharmaceuticals, Efan Pharmaceuticals, Guangshengtang, Health Yuan, including a number of pharmaceutical companies have issued organizational structure adjustment, increase innovation investment informationIndustry insiders believe that with the continuous improvement of China's pharmaceutical innovation environment, generic drug profit margins gradually narrowed, will further force enterprises to the pharmaceutical innovation transformationIn this context, enterprise innovation momentum is enhanced, innovation will continue to emerge, benefiting more patientsof course, in addition to pharmaceutical companies, with the continuous development of China's pharmaceutical industry, its product function and technical requirements are also constantly enriched and complexAnd because domestic enterprises start late, the overall technical level is low, the homogenization of products between enterprises also has more and more serious phenomenonTherefore, in order to seek a differentiated competitive route, get rid of the "follower" roleMany pharmaceutical machine enterprises also start from their own actual situation, focusing on enterprises to highlight the advantages, at the same time through innovation and research and development to make up for the shortcomings, to create a competitive pointit is understood that in the continuous development of intelligent, automated technology, many powerful pharmaceutical machine enterprises have been carrying out automated production lines, intelligent factory layout;Get rid of "imitation", high-end talent to expand into a keyin the technology-driven era, the core competitiveness of enterprises from innovation, from the strength of research and development, so the innovation ability of research and development personnel is also very importantSo how can companies improve the innovation ability of research and development personnel?first of all, enterprises should cultivate a good environment for innovationTo form an "innovation-oriented" cultural atmosphere, establish a mechanism to stimulate innovation, use innovation as one of the criteria for evaluating the ability of professional and technical personnel, establish a relaxed working environment, allow to try and explore, enlighten innovative thinking, establish innovative mechanism, stimulate everyone's desire for innovation and creativitySecondly, we should pay attention to and understand the new technology and innovation dynamics of the industry in real time, grasp the current competitive technical strength, development trend, and fully learn from, analyze and utilizeit is understood that there are many domestic pharmaceutical companies are through more competitive salary treatment, positions and the future development of new career opportunities and other conditions to attract more professional talent to join, with a view to forming a stronger talent team, to help enterprise development more robustin short, regardless of whether pharmaceutical companies are due to transformation innovation or market shuffle and other reasons, talent is the key factor of enterprise competition How to tap more talents and retain talents will be an important course that needs long-term learning and exploration in the development of pharmaceutical companies.